Chengdu Pilot (688222.SH): Shareholders plan to transfer 2.05% of shares in an inquiry
On May 17, Ge Longhui (688222.SH) announced that the shareholders that intend to participate in the initial shareholder inquiry and transfer of Chengdu Pilot are Juntian Venture Capital Co., Ltd., Lhasa Economic and Technological Development Zone Huabo Medical Devices Co., Ltd.; the total number of shares to be transferred by the seller is 8,200,000 shares, accounting for 2.05% of Chengdu Xiandao's total share capital; this inquiry transfer is a private transfer and will not be carried out through centralized bidding transactions. The transferee transfers the transferred shares through an inquiry, and cannot be transferred within 6 months after the transfer.
Chengdu Pilot discloses performance report: core business is recovering for the better
The Innovation Capability Matrix continues to unleash growth potential in Chengdu, April 25, 2024/PRNewswire/ -- On the evening of April 24, Chengdu Pilot Pharmaceutical Development Co., Ltd. (stock code: 688222.SH, hereinafter referred to as “Chengdu Pilot” or “Company”) announced the 2023 Annual Report and the 2024 First Quarter Report (hereinafter referred to as “Annual Report” and “Quarterly Report”, respectively). Since 2023, with the gradual resumption of cross-border exchanges at home and abroad, the company has further optimized its international and domestic market strategies and continued to expand its business scope and partners.
Chengdu Pioneer (688222.SH) announced its 2023 annual results, with net profit of 40.72 million yuan, an increase of 61.16% over the previous year
Chengdu Pioneer (688222.SH) disclosed its 2023 annual report, and the company achieved revenue of 3 in 2023...
Are HitGen Inc.'s (SHSE:688222) Mixed Financials The Reason For Its Gloomy Performance on The Stock Market?
It is hard to get excited after looking at HitGen's (SHSE:688222) recent performance, when its stock has declined 22% over the past three months. It seems that the market might have completely ignor
Chengdu Pilot (688222.SH): AI models are all self-developed or jointly developed with partners, and there is no external procurement
Gelonghui, March 21丨Chengdu Xiandao (688222.SH) said on the interactive platform that at present, Chengdu Pilot's AI technology mainly focuses on molecular discovery and optimization, training and iteration of experimental data based on large model+DEL screening test data, aimed at expanding the space of compounds with multiple target types, generating new molecules, improving compound properties, and increasing compound accessibility. The AI models pioneered in Chengdu were all developed in-house or jointly with partners, and there was no external procurement. As far as traditional Internet companies are concerned, the characteristics of Chengdu Pioneer in AI pharmaceuticals are: 1) Pilot's AI model has a larger number of actual experiments
Chengdu Pilot (688222.SH): It has nothing to do with the scope of restrictions in the draft Biosafety Act
Gelonghui, March 21丨Chengdu Xianjiao (688222.SH) said on an interactive platform that the company has also recently been concerned about statements and industry-related events in the US House of Representatives draft “Biosafety Act” involving restrictions on the use of genetic substances such as human genes by Chinese biotechnology companies. We would also like to explain: Since its establishment in 2012, Chengdu Xiantao has been focusing on the discovery and optimization of small molecules and new nucleic acid drugs, relying on DNA-coding compound library technology (including DEL library design, synthesis and expanded application), drug design based on molecular fragments and three-dimensional structural information Technology (FBDD/SB
Chengdu Pilot (688222.SH): Exploring various AI drug prediction, molecular generation, and optimization models
GLONGHUI, March 21丨Chengdu Xiandao (688222.SH) said on an interactive platform that in 2021, the company and Cambridge Molecular (Cambridge Small Molecule) announced the establishment of an exclusive alliance to efficiently provide potentially active, more readily available compounds for drug targets and accelerate compounds on Chengdu's leading DNA-coding Compound Library (DEL) technology platform, in combination with Cambridge Molecular's highly optimized deep machine learning system for DEL Verification of activity and widening of compound emptiness
Market Participants Recognise HitGen Inc.'s (SHSE:688222) Revenues Pushing Shares 42% Higher
HitGen Inc. (SHSE:688222) shares have had a really impressive month, gaining 42% after a shaky period beforehand. Unfortunately, the gains of the last month did little to right the losses of the la
Does HitGen (SHSE:688222) Have A Healthy Balance Sheet?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says 'The biggest investment risk is not the volatility of prices, but whether you will
Chengdu Pioneer (688222.SH) performance report: 2023 net profit of 43.9437 million yuan, a year-on-year increase of 73.92%
On February 23, Ge Longhui (688222.SH) announced the 2023 annual results report. During the reporting period, the company achieved operating income of 371.6596 million yuan, an increase of 12.74% year on year; achieved net profit attributable to the owner of the parent company of 43.94 million yuan, an increase of 73.92% year on year; realized net profit attributable to the owner of the parent company after deducting non-recurring profit and loss of 3.297,700 yuan, a year-on-year decrease of 73.61%.
Hox Therapeutics and Vernalis Announce a Drug Discovery Collaboration in Oncology
CHENGDU, China, Feb. 20, 2024 /PRNewswire/ -- Hox Therapeutics Ltd ("Hox") a private biotechnology company developing highly targeted cancer therapies and Vernalis (R&D) Ltd ("Vernalis"), a fully owne
Chengdu Pilot (688222.SH): Juntian Investment and Juntian Venture Capital reduced their total shareholding by 4.40%, and their shareholding ratio fell below 5%
Gelonghui, Feb. 19 | Chengdu Pioneer (688222.SH) announced that the company recently received the “Simplified Equity Change Report” from Juntian Investment and Juntian Venture Capital. From May 13, 2021 to February 8, 2024, Juntian Investment and Juntian Venture Capital reduced their holdings of the company's unrestricted tradable shares by a total of 176.33,800 shares through centralized bidding transactions and bulk transactions, accounting for 4.40% of Chengdu Xiandao's total share capital; after this change in equity, the above entities held 4.999991% of the company's shares. East.
Chengdu Pilot (688222.SH): Net profit is expected to increase by 50.4% to 97.89% year-on-year in 2023
Gelonghui, January 29丨Chengdu Pilot (688222.SH) announced that it is expected to achieve operating revenue of 365.0 million yuan to 380.01 million yuan in 2023. Compared with the same period last year, it will increase 353.5 million yuan to 50.35 million yuan, an increase of 10.72% to 15.27% over the previous year. The net profit attributable to the owners of the parent company is expected to be 38.0 million yuan to 50 million yuan in 2023, an increase of 12.734 million yuan to 24.734 million yuan compared with the same period last year, an increase of 12.734 million yuan to 24.734 million yuan, an increase over the previous year
Does This Valuation Of HitGen Inc. (SHSE:688222) Imply Investors Are Overpaying?
Key Insights The projected fair value for HitGen is CN¥10.16 based on 2 Stage Free Cash Flow to Equity HitGen's CN¥12.51 share price signals that it might be 23% overvalued HitGen's peers seem to
Can Mixed Fundamentals Have A Negative Impact on HitGen Inc. (SHSE:688222) Current Share Price Momentum?
HitGen (SHSE:688222) has had a great run on the share market with its stock up by a significant 15% over the last week. However, we decided to pay attention to the company's fundamentals which don't
HitGen Inc.'s (SHSE:688222) Last Week's 5.6% Decline Must Have Disappointed Private Companies Who Have a Significant Stake
Key Insights HitGen's significant private companies ownership suggests that the key decisions are influenced by shareholders from the larger public 53% of the business is held by the top 5 sharehold
Chengdu Pioneer (688222.SH): Cooperate with Tencent AI Lab in 2021 to jointly design and develop a molecular skeleton transition algorithm
Gelonghui, December 5, Chengdu Pioneer (688222.SH) said on an interactive platform that Chengdu Pioneer, as an innovation-driven biotechnology company focusing on early drug discovery, has always paid close attention to the progress of AI in the field of drug development and has continued to conduct related exploration and research. First, in 2021, Chengdu Pioneer collaborated with Tencent AI Lab to jointly design and develop a molecular skeleton transition algorithm (GraphGMVAE). This algorithm can generate molecules with similar activity and different skeletons while maintaining the molecular side chain unchanged. At the same time, we have also proposed a set of molecular advances
Time To Worry? Analysts Are Downgrading Their HitGen Inc. (SHSE:688222) Outlook
One thing we could say about the analysts on HitGen Inc. (SHSE:688222) - they aren't optimistic, having just made a major negative revision to their near-term (statutory) forecasts for the organizatio
Chengdu Pilot (688222.SH): At present, more than 200 targets have been screened for customers
Gelonghui November 2 | Chengdu Pioneer (688222.SH) said in a survey of specific targets on November 1 that the establishment and selection of new targets will face resource constraints for major pharmaceutical companies and Biotech. Relatively speaking, the R&D capabilities and R&D capital of major pharmaceutical companies are at the top of the pyramid, and there are resources to explore more cutting-edge targets. Some overseas customers are leading the way in exploring new target mechanisms. If a customer has a new target in demand, as long as Chengdu can lead the way in terms of technology, then they can accept it under the principle of exclusion. At present, Chengdu Pioneer has completed more than 200 targets for customers
[BT Financial Report Instantaneous Analysis] Chengdu Pilot 2023 Third Quarter Report: Total assets are growing steadily, net profit has increased dramatically
This financial report was announced at 16:25:45 2023-10-27, Chengdu Leading Drug Development Co., Ltd. (stock code: 688222) is an enterprise focusing on the discovery and optimization of new drugs for small molecules and nucleic acids. Relying on four core technology platforms, including DEL technology, drug design technology, oligonucleic acid drug development platform and targeted protein degradation platform, and other key new drug development capabilities, the company is committed to building an internationally leading new drug development system. The company provides the pharmaceutical industry with new molecular facts at different stages by providing new drug research and development services, project transfer, and drug marketing
No Data